May 11, 2016 / 12:42 PM / 2 years ago

BRIEF-Pediapharm receives FDA supplement approval regarding Naproxen suspension

May 11 (Reuters) - Pediapharm Inc :

* Approval triggered second and final payment of us$2 million in cash

* Pediapharm receives fda supplement approval regarding naproxen suspension in the us, receives additional us$2 million from atnahs pharma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below